Obeticholic Acid for Primary Biliary Cholangitis [PDF]
Biomedicines, 2022 Primary biliary cholangitis (PBC) is a rare autoimmune cholestatic liver disease that may progress to fibrosis and/or cirrhosis. Treatment options are currently limited.
Annarosa Floreani +2 more
doaj +4 more sources
Inhibition of ACOX1 enhances the therapeutic efficacy of obeticholic acid in treating non-alcoholic fatty liver disease and mitigates its lipotoxicity [PDF]
Frontiers in PharmacologyBackground and aims:High-dose Obeticholic acid exhibits promise for non-alcoholic fatty liver disease (NAFLD) treatment but can induce lipotoxicity.
Yuping Yang +8 more
doaj +4 more sources
Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection [PDF]
Hepatic Medicine: Evidence and Research, 2016 Christopher L Bowlus Division of Gastroenterology and Hepatology, University of California Davis, Davis, CA, USA Abstract: Primary biliary cholangitis (PBC), previously known as primary biliary “cirrhosis”, is a rare autoimmune liver disease ...
Bowlus CL
doaj +6 more sources
Transcriptional and Post-Transcriptional Anticholestatic Mechanisms of Obeticholic Acid in Lipopolysaccharide-Induced Cholestasis [PDF]
PharmaceuticsBackground/Objectives: Sepsis-induced cholestasis is caused by the release of inflammatory cytokines from lipopolysaccharide (LPS), a component of Gram-negative bacteria. No established therapy exists for this condition.
María Valeria Razori +6 more
doaj +4 more sources
Obeticholic Acid—A Pharmacological and Clinical Review [PDF]
Future Pharmacology, 2023 Obeticholic acid (OCA) or 6-alpha-ethyl-chenodeoxycholic acid is a semisynthetic modified bile acid derivative that acts on the farnesoid X receptor (FXR) as an agonist with a higher potency than bile acid.
Caezaan Keshvani +2 more
doaj +3 more sources
Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice [PDF]
Frontiers in Pharmacology, 2022 Objective: Obeticholic acid (OCA), a potent farnesoid X receptor (FXR) agonist, is a promising drug for nonalcoholic fatty liver disease (NAFLD); however, it can cause liver injury, especially at high doses.
Chuangzhen Lin +8 more
doaj +4 more sources
Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status. [PDF]
Euroasian J Hepatogastroenterol, 2022 Nonalcoholic fatty liver disease (NAFLD) is one of the major and prevalent liver diseases from the national and global perspectives. It appears that considerable numbers of the general population have been suffering from NAFLD. When a patient with NAFLD also exhibits inflammation of the liver, the condition is regarded as nonalcoholic steatohepatitis ...
Roy PP +5 more
europepmc +4 more sources
Tenascin C-Guided Nanosystem for Precision Delivery of Obeticholic Acid in Liver Fibrosis Therapy [PDF]
PharmaceuticsObjective: Liver fibrosis, a hallmark of chronic liver diseases, is characterized by excessive extracellular matrix (ECM) deposition and scar tissue formation.
Yawen Wang +6 more
doaj +4 more sources
Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice [PDF]
PLoS ONE, 2022 Background Suppression of cardiac iinflammasome, which can be inhibited by Farnesoid X receptor (FXR) agonist, can ameliorate cardiac inflammation and fibrosis.
Szu-Yu Liu +7 more
doaj +3 more sources
27558 Obeticholic acid (OCALIVA ®) protects against 2,8-dihydroxyadenine nephropathy in mice [PDF]
Journal of Clinical and Translational Science, 2021 IMPACT: This work may lead to new treatments for crystalline nephropathies. OBJECTIVES/GOALS: This study investigated obeticholic acid (OCALIVA ®) as a potential treatment for 2,8-dihydroxyadenine (2,8-DHA) nephropathy using a mouse model.
Bryce Jones +9 more
doaj +2 more sources